Zimmer Biomet Holdings, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98956P1021
USD
93.16
0.06 (0.06%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Zimmer Biomet Holdings, Inc. stock-summary
stock-summary
Zimmer Biomet Holdings, Inc.
Pharmaceuticals & Biotechnology
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Company Coordinates stock-summary
Company Details
345 E Main St , WARSAW IN : 46580-2746
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 174 Schemes (56.32%)

Foreign Institutions

Held by 379 Foreign Institutions (16.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Larry Glasscock
Independent Non-Executive Chairman of the Board
Mr. Bryan Hanson
President, Chief Executive Officer, Director
Mr. Christopher Begley
Independent Director
Ms. Betsy Bernard
Independent Director
Ms. Gail Boudreaux
Independent Director
Mr. Michael Farrell
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,077 Million
(Quarterly Results - Jun 2025)
Net Profit:
153 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 31,612 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

47.75%

stock-summary
Debt Equity

0.56

stock-summary
Return on Equity

8.51%

stock-summary
Price to Book

2.52